Lifecore Biomedical ($LFCR) $3.75M Investor Settlement
Lifecore Biomedical agreed to a settlement with $LFCR investors to resolve claims that it misled them about internal controls, inventory management, and financial reporting risks.
Outline:
Lifecore assured investors about its financial performance and operational stability between 2021 and 2023. Investors later alleged the company failed to disclose serious internal control and inventory management problems. As accounting issues surfaced and the company missed filings and received default notices, the stock declined sharply. Investors filed suit and Lifecore later reached a tentative settlement to resolve the claims.
Timeline:
September 2021–April 2023: Lifecore allegedly issued misleading statements about inventory and financial performance.
April 21, 2023: Lifecore announced it would miss its SEC filing deadline for its quarterly report.
May 2023: The company received a default notice from lenders.
July 2023: Lifecore disclosed material weaknesses in internal controls.
August 2023: The stock declined, and investors filed a class action complaint.
November 2025: The parties settled.
Background:
Lifecore Biomedical, formerly known as Landec Corporation, manufactures pharmaceutical-grade hyaluronan-based products used in medical and pharmaceutical applications. During the class period, the company presented its operations and financial reporting as stable while emphasizing growth and operational strength.
Investors later alleged that Lifecore failed to disclose persistent inventory management problems and accounting deficiencies. According to the claims, these issues affected the company’s financial reporting and would ultimately require restatements and additional review of its financial statements.
In April 2023, Lifecore warned it would not be able to file its quarterly report on time due to internal accounting problems. The delays triggered loan covenant breaches and led to default notices from lenders.
On July 10, 2023, the company disclosed material weaknesses in its internal controls, contradicting earlier assurances about the reliability of its financial reporting. Following these disclosures, $LFCR declined and investors alleged they suffered losses due to misleading statements about the company’s financial health.
What Can Investors Expect Now?
Lifecore Biomedical has agreed to a settlement with $LFCR investors to resolve claims tied to disclosures about internal controls, inventory management, and financial reporting risks.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.
Frequently Asked Questions
All persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive, and were damaged thereby
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.